<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00157378</url>
  </required_header>
  <id_info>
    <org_study_id>01GI9933-P2.1.2.1</org_study_id>
    <nct_id>NCT00157378</nct_id>
  </id_info>
  <brief_title>Optimization of Acute Treatment in First Episode Schizophrenia</brief_title>
  <official_title>Optimization of Acute Treatment in First Episode Schizophrenic Patients by New Pharmacological Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Research Network On Schizophrenia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Psychiatry University of Bonn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Psychiatry University FU Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Göttingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mainz University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universität Duisburg-Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Mannheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Martin-Luther-Universität Halle-Wittenberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Wuerzburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <brief_summary>
    <textblock>
      The study is a multicenter, double-blind, randomized, parallel-group study with first episode
      schizophrenic patients. During a treatment phase of 8 weeks the patients are treated with
      Risperidone or Haloperidol. Aim of the project is to compare the effects of the atypical
      neuroleptic Risperidone with those of the conventional neuroleptic Haloperidol and to
      evaluate whether the assumed advantages of atypical neuroleptics compared to conventional
      neuroleptics are also present when both medications are administered in rather low daily
      dosages (min. 2 mg/d; max. 8 mg/d).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Considering that first episode schizophrenic patients compared to multiple episode patients
      respond to lower dosages of neuroleptics, the study aims to reach neuroleptic response under
      the lowest possible dosage of the study medication (haloperidol or risperidone). Therefore
      the initial dosage of the study medication is 2 mg/d. Depending on the patients`
      symptomatology, the daily dosage of the study medication can be increased by 2 mg in weekly
      intervals up to a maximum dosage of 8 mg/d. Patients with the diagnosis of schizophrenia
      (F20, according to ICD-10-criteria) are consecutively enrolled in the study. The patients are
      assessed at weekly intervals during the acute inpatient treatment phase of 8 weeks. Apart
      from the weekly psychopathological characterisation additionally neuropsychobiological data
      are assessed at the time of admission and at the end of the study. Major questions of the
      study are, whether patients, who have been treated with risperidone compared with those, who
      have been treated with haloperidol show a better treatment outcome regarding negative
      symptoms and exhibit fewer extra-pyramidal motor side effects. Furthermore it is
      hypothesised, that the treatment with Risperidone has better effects on cognitive
      disorders/dysfunctions and depressive symptoms and that the patients, who receive Risperidone
      are more compliant and have a higher quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2000</start_date>
  <completion_date>December 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>weekly assessment of psychopathology (e.g.PANSS)and side-effects</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>cognitive disability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>depression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>life quality at time of admission &amp; end of study</measure>
  </secondary_outcome>
  <enrollment>300</enrollment>
  <condition>Schizophrenia, First-Episode</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone, Haloperidol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ICD-10 criteria for first episode schizophrenia

          -  age between 18 and 55

          -  informed consent

        Exclusion Criteria:

          -  legal reasons

          -  insufficient knowledge of the german language

          -  substance abuse or addiction

          -  pregnancy

          -  serious physical illness

          -  organic brain disease

          -  contraindication to neuroleptic treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Jürgen Möller, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Psychiatry, Ludwig-Maximilians-University Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry, Ludwig-Maximilians-University</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.kompetenznetz-schizophrenie.de/rdkns/325.htm</url>
  </link>
  <verification_date>January 2000</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>September 8, 2005</last_update_submitted>
  <last_update_submitted_qc>September 8, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2005</last_update_posted>
  <keyword>first episode,</keyword>
  <keyword>schizophrenia,</keyword>
  <keyword>atypical neuroleptics,</keyword>
  <keyword>negative symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

